Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 18,752 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Obstetric Pain, Pain
Interventions: Virtual Reality; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy Volunteer
Interventions: Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing, Pharmacokinetic sampling - AZ5140 and AZ7550; Procedure · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Overland Park, Kansas • Minneapolis, Minnesota

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Dasatinib, Paclitaxel, and Carboplatin; Drug
Lead sponsor: AA Secord; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Tampa, Florida • Durham, North Carolina

Conditions: Hepatic Impairment
Interventions: ALKS 5461; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions: Allodepleted T Cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Advanced Solid Tumor or Lymphoma
Interventions: BJ-005; Biological
Lead sponsor: BJ Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Port Saint Lucie, Florida + 3 more

Conditions: Non-small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 37
States / cities: Tucson, Arizona • Duarte, California • Glendale, California + 33 more

Conditions: Diabetic Foot
Interventions: GAM501, Placebo, Standard of care; Biological · Other
Lead sponsor: Tissue Repair Company; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 29
States / cities: Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 24 more

Conditions: Bipolar I Disorder
Interventions: quetiapine fumarate, lithium, divalproex; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 36
States / cities: Birmingham, Alabama • Beverly Hills, California • Chula Vista, California + 33 more

Conditions: Meniscus Tear
Interventions: AM3101, Saline Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 40 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Cincinnati, Ohio • Cleveland, Ohio • Portland, Oregon

Conditions: Tumors
Interventions: ASA404, Cetuximab, Carboplatin, Paclitaxel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
Interventions: Sirolimus Albumin-bound Nanoparticles, Pazopanib hydrochloride; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HPV-Related Carcinoma
Interventions: IBRX-042; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 2
States / cities: El Segundo, California • Houston, Texas

Conditions: Lung Cancer
Interventions: comparative genomic hybridization, fluorescence in situ hybridization, gene expression analysis, microarray analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, medical chart review, diagnostic bronchoscopy; Genetic · Other · Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 689 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2016
U.S. locations: 4
States / cities: Nashville, Tennessee

Conditions: Healthy Volunteer
Interventions: GDC-0032 Phase III Tablet, GDC-0032 Tablet, GDC-0032 Capsule; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV LID ΔM2-2 1030s vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 24 Months
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Laurel, Maryland

Conditions: Cervical Spinal Cord Injury, Spine Injury, Spinal Cord Trauma
Interventions: AST-OPC1; Biological
Lead sponsor: Lineage Cell Therapeutics, Inc.; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 9
States / cities: La Jolla, California • Los Angeles, California • San Jose, California + 6 more

Conditions: Advanced Prostate Cancer
Interventions: HPN424 Fixed IV 1.3 to 150 ng/kg, HPN424 Prime Step IV 36 ng/kg Target, HPN424 1 Prime Step IV 225-300 ng/kg Target, HPN424 2 Prime Step IV 300 ng/kg Target, HPN424 2 Prime Step IV 450 ng/kg Target, HPN424 Fixed SC; Biological
Lead sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older · Male only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: AZD4360; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Santa Monica, California • Providence, Rhode Island • Houston, Texas

Conditions: Lung Cancer
Interventions: therapeutic thoracoscopy, video-assisted surgery; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 112
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 72 more

Conditions: Sarcoma
Interventions: cisplatin, doxorubicin hydrochloride, isolated limb perfusion, conventional surgery, brachytherapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2000
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: CAT 354; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Glendale, California

Conditions: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Interventions: Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 4 more

Conditions: Colorectal Neoplasms
Interventions: hMN14 (labetuzumab); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Seattle, Washington

Search by objective public record fields.

Virtual Reality in Obstetric Patients

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene

A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

IBRX-042 In Participants With HPV-Associated Tumors

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

Study of HPN424 in Patients With Advanced Prostate Cancer

Study for AZD4360 in Participants With Advanced Solid Tumours

Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer

Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma

A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery